Vladimir Coric
Chairman & CEODr. Vladimir Coric, also known as Vlad, MD, is Independent Non-Employee Director of Veradermics, Incorporated from September 2021. Dr. Coric is Independent Director of Royalty Pharma plc from April 8, 2025. He was an Independent Director at Revance Therapeutics, Inc. since March 01, 2023 until February 2025. He is Director at Pyramid Biosciences Inc. since August 2020. He had been Independent Director of Social Capital Suvretta Holdings Corp. I since June 29, 2021 until 2022. He serves as Chairman and Chief Executive Officer at Biohaven Ltd. He had been the Chief Executive Officer at Biohaven Pharmaceuticals Holding Company Ltd. since October 2015 until October 03, 2022 and served as its President and had been its Chairman of the Board since December 5, 2021 until October 03, 2022. He also serves as Director of Pyramid Bio and Vita Therapeutics and OLM School of Madison. He has drug development and executive leadership experience. He has experience as the Chief of Inpatient Services at the Yale Clinical Neuroscience Research Unit. He has been an Associate Clinical Professor of Psychiatry at the Yale School of Medicine since July 2001. He is a Co-Inventor of Yale intellectual property related to the use of glutamate modulating agents. From January 2007 to September 2015, he served as a Group Director of Global Clinical Research at Bristol-Myers Squibb Company, focusing both on oncology global clinical research and neuroscience global clinical research and was the Group Director, Neuroscience and Oncology Global Clinical Research. He has been involved in multiple drug development programs including marketed drugs such as NURTEC ODT (rimegepant; CGRP receptor antagonist), Abilify (aripiprazole; partial dopamine agonist), Opdivo (nivolumab; anti-PD1), Yervoy (Ipilimumab; anti-CTLA-4), Daklinza (daclatasvir; NS5A inhibitor) and Sunvepra (asunaprevir; NS3 inhibitor). He had been a Director at Biohaven Pharmaceuticals Holding Company Ltd. since October 2015 until October 03, 2022. He served as the Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as the President of the Connecticut Psychiatric Society. He has several peer-reviewed journal and book publications and has lectured nationally on neurological and psychiatric disorders. He completed his internship at Yale-New Haven Hospital and Residency Training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. He serves as Director of Vita Therapeutics, Inc. He completed his medical residency and fellowship training at Yale. He earned his MD at Wake Forest University School of Medicine and received his BS from University of Connecticut in Physiology and Neurobiology. He was an Honors Scholar in Neurobiology and Physiology at the University of Connecticut.
Positions
- Company NameBiohaven Ltd.Stock CodeBHVNPositionChairman & CEOColleagues
- VCVladimir CoricChairman & CEO
- MBMatthew ButenChief Financial Officer
- KGKimberly GentileSenior Vice President of Clinical Operations
- BDBruce D. CarChief Innovation Officer
- DYDeb YoungSenior Director of Regulatory Affairs & Operations
- DGDouglas GrayCorporate Secretary & Director
- MTMichael Thomas HeffernanLead Independent Director
- GHGregory H. BaileyIndependent Director
- JWJohn Winston ChildsIndependent Director
- Company NameVeradermics, IncorporatedStock CodeMANEPositionIndependent Non-Employee DirectorColleagues
- RWReid WaldmanCEO & Director
- DCDominic CarranoCFO & Treasurer
- TDTimothy DursoChief Technical Officer
- MVMichael V. GrecoGeneral Counsel & Secretary
- MNMark NeumannChief Commercial & Strategy Officer
- PGPatrick Gerald EnrightIndependent Non-Employee Director
- JMJane M. Grant-KelsIndependent Non-Employee Director
- JWJohn Winston ChildsIndependent Non-Employee Director
